Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi

The RTS,S/AS01 malaria vaccine will undergo a pilot vaccination study in sub-Saharan Africa beginning in 2019. RTS,S/AS01 Phase III trials reported an efficacy of 28.3% (children 5–17 months) and 18.3% (infants 6–12 weeks), with substantial variability across study sites. We postulated that the rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Sundos, Parrillo, Matthew, Gutierrez, Andres H., Terry, Frances E., Moise, Leonard, Martin, William D., De Groot, Anne S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062414/
https://www.ncbi.nlm.nih.gov/pubmed/30614773
http://dx.doi.org/10.1080/21645515.2018.1560772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062414/
https://www.ncbi.nlm.nih.gov/pubmed/30614773
http://dx.doi.org/10.1080/21645515.2018.1560772

Ejemplares similares